

## **ACCESS TO DAAS FROM AN ASIAN PERSPECTIVE**

Khwairakpam, G

Second generation direct- acting antivirals (DAAs) for the treatment of hepatitis C has simplified and improved treatment response considerably. Licensed generics from India and other non-licensed generics are making some headway in making affordable quality DAAs curing many across the worlds who needs treatment. However, the process of registration and obtaining marketing approvals have been slow both in the regions where the medicines are manufactured as generics or even by the originators. In India, the DAAs are widely available at a price considered affordable by quite a few and is currently curing patients who either could not access through their public health programs or cannot afford the originator drugs across the globe.